|
|
|
 |
| Location: Home -
Products - Active Pharma Ingredients(API) - Cardiovascular Agents
|
Evacetrapib(LY2484595)
| Catalogue No. : |
C14737 |
| Product Name: |
Evacetrapib(LY2484595) |
| Synonym: |
LY2484595;LY 2484595;LY-2484595 |
| Chemical Name: |
Trans-4-({(5S)-5-[{[3,5-bis(trifluoromethyl)phenyl]methyl}(2-methyl-2H-tetrazol-5- yl)amino]-7,9-dimethyl-2,3,4,5-tetrahydro-1H-benzazepin-1-yl}methyl) cyclohexanecarboxylic acid |
| CAS No. : |
1186486-62-3 |
| Structure : |
|
| Molecular Formula: |
C31H36F6N6O2 |
| Molecular Weight: |
638.65 |
| Purity: |
>98%,ee>99% |
| Usage: |
Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
